Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries

Vaccine

Volumn 24, Issue SUPPL. 3, 2006, Pages

  Lehtinen, Matti ^a,b   Herrero, Rolando ^c   Mayaud, Philippe ^d   Barnabas, Ruanne ^e,f   Dillner, Joakim ^g   Paavonen, Jorma ^a,h   Smith, Peter G ^d  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g LUND UNIVERSITY   (Sweden)

^h UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cervical cancer; Effectiveness; Efficacy; Vaccination

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS VACCINE; WART VIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; HEALTH CARE; HEALTH PROGRAM; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INCIDENCE; LICENSING; LIFESTYLE; LONG TERM CARE; NUTRITIONAL STATUS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SYSTEM ANALYSIS; VACCINATION; VIRUS INFECTION; WART VIRUS; DEVELOPED COUNTRY; IMMUNOLOGY; POSTMARKETING SURVEILLANCE; RESEARCH; REVIEW;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRODUCT SURVEILLANCE, POSTMARKETING; RESEARCH;

EID: 33747891056     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.109     Document Type: Article

References (30)

1. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
2. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
3. Myers E.R., McCrory D.C., Nanda K., Bastian L., and Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151 12 (2000) 1158-1171
4. Lehtinen M., Idanpaan-Heikkila I., Lunnas T., Palmroth J., Barr E., Cacciatore R., et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 17 4 (2006) 237-246
5. Lehtinen M, Apter D, Dubin G, Patama T, Palmroth J, Laukkanen P, et al. Enrollment of 22,000 adolescent women to cancer registry follow-up of long-term human papillomavirus vaccine efficacy. Int J STD AIDS, in press.
6. Garnett G.P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191 Suppl 1 (2005) S97-S106
7. Peltola H., Davidkin I., Paunio M., Valle M., Leinikki P., and Heinonen O.P. Mumps and rubella eliminated from Finland. JAMA 284 20 (2000) 2643-2647
8. Halloran M.E., Struchiner C.J., and Longini Jr. I.M. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 146 10 (1997) 789-803
9. Lehtinen M., and Paavonen J. Effectiveness of preventive human papillomavirus vaccination. Int J STD AIDS 14 12 (2003) 787-792
10. Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 78 6 (1999) 478-485
11. Collins S., Mazloomzadeh S., Winter H., Blomfield P., Bailey A., Young L.S., et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 109 1 (2002) 96-98
12. Hemminki K., Dong C., and Vaittinen P. Familial risks in cervical cancer: is there a hereditary component?. Int J Cancer 82 6 (1999) 775-781
13. Lehtinen M., and Paavonen J. Efficacy of preventive human papillomavirus vaccination. Int J STD AIDS 12 12 (2001) 771-776
14. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
15. Koskela P., Anttila T., Bjorge T., Brunsvig A., Dillner J., Hakama M., et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 85 1 (2000) 35-39
16. Hughes J.P., Garnett G.P., and Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 13 6 (2002) 631-639
17. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 5 (2006) e138
18. Luostarinen T., Lehtinen M., Bjorge T., Abeler V., Hakama M., Hallmans G., et al. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer 40 7 (2004) 1058-1065
19. Laukkanen P., Koskela P., Pukkala E., Dillner J., Laara E., Knekt P., et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 84 Pt 8 (2003) 2105-2109
20. Brookmeyer R., and Chen Y.Q. Person-time analysis of paired community intervention trials when the number of communities is small. Stat Med 17 18 (1998) 2121-2132
21. Lehtinen M, Kaasila M, Pasanen K, Kosunen E, Isaksson R, Korpivaara E, et al. Seroprevalence ATLAS of infections with oncogenic and non-oncogenic human paillomaviruses in Finland in the 1980s and 1990s. Int J Cancer, in press.
22. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 2 (2004) 205-216
23. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 9 (2001) 533-543
24. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 87 11 (1995) 796-802
25. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 1 (2003) 63-73
26. Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet 366 9490 (2005) 991-998
27. The Gambia Hepatitis Study Group. The Gambia hepatitis intervention study. Cancer Res 47 21 (1987) 5782-5787
28. The Gambia Hepatitis Study Group. Hepatitis B vaccine in the expanded programme of immunisation: the Gambian experience. Lancet 1 8646 (1989) 1057-1059
29. Chang M.H., Chen T.H., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 11 21 (2005) 7953-7957
30. Viviani S., Jack A., Hall A.J., Maine N., Mendy M., Montesano R., et al. Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age. Vaccine 17 23-24 (1999) 2946-2950